Piqray: Transforming the Landscape of PIK3CA-Mutated Breast Cancer Treatment

Piqray (alpelisib) is an FDA-approved kinase inhibitor for use in conjunction with fulvestrant, intended for the treatment of advanced or metastatic breast cancer in postmenopausal women and men. This treatment is specifically designed for cases characterized by hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA-mutated conditions. 

Piqray tablets, containing alpelisib, are designed for oral use. The recommended daily dose is 300 mg, consisting of two 150 mg tablets taken orally with food. In response to adverse reactions, healthcare providers may opt for measures like dose interruption, reduction, or discontinuation. PIQRAY is offered in tablet form with strengths of 50 mg, 150 mg, and 200 mg.

Approximately 40% of HR+ advanced breast cancer patients have a mutation that may activate the PI3K pathway called PIK3CA mutations. These mutations are associated with resistance to endocrine therapy, disease progression, and a poor prognosis. Piqray works by inhibiting the PI3K pathway, which is activated by PIK3CA mutations, and may help overcome endocrine resistance in HR+ advanced breast cancer.

In the phase 3 clinical trial, Piqray in combination with fulvestrant demonstrated improved progression-free survival compared to fulvestrant alone in patients with HR+/HER2-, PIK3CA-mutated, advanced, or metastatic breast cancer, as detected by an FDA-approved test following progression on or after endocrine-based regimen. 

Piqray has a manageable safety profile, with common side effects such as diarrhea, nausea, and vomiting. The FDA approval of Piqray marks the first-ever treatment specifically for HR+/HER2- advanced breast cancer with a PIK3CA mutation.

In conclusion, Piqray represents a significant advancement in the treatment of HR+/HER2- advanced breast cancer with a PIK3CA mutation. Its mechanism of action, targeting the PI3K pathway, offers a promising approach to overcoming endocrine resistance in HR+ advanced breast cancer. As more research and clinical trials are conducted, the future of Piqray in cancer treatment will become clearer, and its impact on cancer care is expected to grow.

If you are looking to buy Piqray online, available exclusively in the US and Europe, Sansfro Health provides a reliable solution. Committed to simplifying the importation process, Sansfro Health furnishes precise pricing details for a seamless experience. The importation process is facilitated by Sansfro with authentic pricing and comprehensive assistance.

Individuals interested in importing medication must submit a valid prescription, identity proof, healthcare professional details, and current address. The Sansfro team initiates the import license application, ensuring access to the necessary medication upon government approval. For inquiries regarding the price of Piqray in India and to comprehend the importation procedure, individuals can reach out to the Patient Support Team at (+91) 9315705373 or via email at help@sansfro.com. 

Reference:

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf 
2. https://www.us.piqray.com 
3. https://www.prnewswire.com/news-releases/novartis-data-highlight-efficacy-of-piqray-in-hrher2–metastatic-breast-cancer-with-a-pik3ca-driver-mutation-immediately-post-cdk46i-301441879.html 
4. https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer 
5.  https://www.breastcancer.org/treatment/targeted-therapy/piqray